Grupo para la caracterización molecular de las neoplasias hematológicas
Universitat de València
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Universitat de València (18)
2023
-
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)
Leukemia
-
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY
Leukemia, Vol. 37, Núm. 2, pp. 339-347
-
Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study
BMJ open, Vol. 13, Núm. 7, pp. e071371
2021
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60
-
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
Blood Cancer Journal, Vol. 11, Núm. 5
2020
-
Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype
Scientific Reports, Vol. 10, Núm. 1
-
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols
European Journal of Haematology, Vol. 104, Núm. 3, pp. 162-169
-
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis
Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158
-
Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-pembresid clinical trial
Cancers, Vol. 12, Núm. 12, pp. 1-13
2019
-
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial
Digestive and Liver Disease, Vol. 51, Núm. 4, pp. 529-535
2018
-
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
Leukemia, Vol. 32, Núm. 1, pp. 21-29
2017
-
Adalimumab vs azathioprine in the prevention of postoperative Crohn's disease recurrence. A GETECCU randomised trial
Journal of Crohn's and Colitis, Vol. 11, Núm. 11, pp. 1293-1301
2016
-
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis
Blood, Vol. 127, Núm. 9, pp. 1151-1162
2015
-
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: A matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies
Annals of Hematology, Vol. 94, Núm. 8, pp. 1347-1356
2014
-
Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database
Nature Genetics, Vol. 46, Núm. 2, pp. 107-115
-
Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients
Annals of Hematology, Vol. 93, Núm. 2, pp. 299-307
2011
-
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy
Haematologica, Vol. 96, Núm. 10, pp. 1470-1477
2007
-
Recomendaciones para la prevención, diagnóstico y tratamiento de osteonecrosis de los maxilares (ONM) en pacientes con cáncer tratados con bisfosfonatos
Medicina Oral, Patologia Oral y Cirugia Bucal, Vol. 12, Núm. 4, pp. 279-283